Startup · $45m raised · Healthcare
Tissue expander system for breast reconstruction
Palo Alto
Every investor coverage indicates participated in a round AirXpanders raised.
The transaction that ended AirXpanders's run as a startup, per published coverage. It closes the funding history too, where it is the ladder's last rung.
| Bought by | Kind | Announced | Price | Sources |
|---|---|---|---|---|
| - | IPO | undated | - | GBS Ventures (Wed 3 Apr 2019), GBS Ventures (Fri 10 Mar 2017), GBS Ventures (Thu 15 Oct 2015) |
Companies AirXpanders acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming AirXpanders. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
ASX-listed medical device maker AirXpanders is winding down, cutting staff to about eight, halting product sales and support, and expecting a US Chapter 7 bankruptcy filing by late July 2019.
ASX-listed medical device maker AirXpanders, headquartered in California, extends its voluntary trading suspension while reviewing financial and strategic alternatives, and postpones its 2019 annual stockholder meeting.
ASX-listed breast reconstruction device maker AirXpanders, based in California, has appointed financial services firm Cowen to review financial and strategic options; no transaction has been agreed.
ASX-listed medical device maker AirXpanders announced a restructuring cutting roughly 45% of staff and about a third of quarterly cash use, and said it is pursuing capital raising options via a preliminary SEC filing.
AirXpanders, an ASX-listed medical device maker headquartered in California, halted trading in its securities while reviewing operations, facing an expected loan covenant breach, and weighing options for a future capital raise.
Device maker AirXpanders marks 4,000 AeroForm tissue expanders placed globally, noting growing US and Australian hospital adoption, a rebuilt US sales team and reduced spending; the company trades on the ASX as AXP.
Medical device maker AirXpanders completed a private placement first announced in August 2018, issuing shares to Vivo Ventures and its chairman Barry Cheskin to raise about US$3.4 million, notifying the ASX accordingly.
Medical device maker AirXpanders appoints US industry veteran Frank Grillo as chief executive, succeeding interim leader Scott Murcray, with co-founder Barry Cheskin welcoming the hire ahead of Grillo fronting July's investor call.
AirXpanders' quarterly update: steady revenue, cost cuts and headcount reductions, Scott Murcray interim CEO while the board searches for a permanent chief, and a planned move to Australian distributors.
ASX-listed medical device maker AirXpanders, based in California, released its 2017 full-year results, reporting growing AeroForm sales, a US$34 million equity placement, and a US$15 million debt facility with Oxford Finance.
US-based medical device maker AirXpanders, listed on the ASX, proposes adding Liz Hammack to its board as co-founder Teddy Shalon departs and fellow director Dennis Condon faces re-election at its May annual meeting.
AirXpanders wins US regulator clearance for an improved film material in its breast reconstruction device, reporting sales hires and clinic conversions as its American rollout begins ahead of schedule.
A breast reconstruction device maker presented its needle-free tissue expansion technology at a Barcelona surgical conference, where a US trial investigator shared results and the chief executive outlined plans for European availability.
ASX-listed medical device maker AirXpanders, based in California, has committed investors for a A$45 million private placement at A$0.92 per CDI, with Canaccord Genuity as sole lead manager, to fund its US commercial launch.
Also GBS Ventures·GBS Ventures
The ASX-listed medical device maker AirXpanders has published an investor presentation, weeks after US regulators granted clearance for its tissue expansion product.
Breast reconstruction device maker AirXpanders gained US regulator clearance for its needle-free AeroForm tissue expander, enabling a January 2017 American launch; an amended CE Mark also covers an enhanced version.
AirXpanders shared new clinical data for its AeroForm breast reconstruction device at a major plastic surgery meeting, showing faster expansion times, and an Australian study author received a best-paper award.
ASX-listed breast reconstruction device maker AirXpanders secured commitments for a 20 million dollar placement at 76 cents per CDI, and appointed Scott Murcray CFO/COO ahead of its planned US launch.
AirXpanders reported positive results from its XPAND pivotal trial of the AeroForm tissue expander at a major plastic surgery meeting, showing faster expansion than saline devices, as it seeks US FDA clearance.
AirXpanders reports brisk early adoption of its AeroForm tissue expander after its Australian launch, citing surgeon training, hospital onboarding, and steps toward a US market entry.
AirXpanders' needle-free breast-reconstruction device is showcased at a major American plastic surgery conference, with trial results presented; the ASX-listed company awaits a US regulatory decision.
Also GBS Ventures·GBS Ventures
Breast reconstruction device maker AirXpanders has lodged a 510(k) regulatory submission with US authorities for its needle-free AeroForm tissue expander, following positive clinical trial results, as it moves toward entering the American market.
ASX-listed breast reconstruction device maker AirXpanders reports its pivotal XPAND trial met its primary endpoint, with results to go to the US regulator and be presented at a plastic surgery meeting in Boston.